Ads
related to: dabrafenib and trametinib lung cancer- Lung Cancer Screening
Learn About Lung Cancer Screening.
Is This the Right Test for You?
- Virtual Second Opinions
Get Peace of Mind from Home.
Review Your Diagnosis & Treatment.
- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Lung Cancer Signs
Free Lung Cancer Treatment Guide.
Lung Cancer Signs and Symptoms.
- Lung Cancer Screening
Search results
Results from the WOW.Com Content Network
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
Drug resistance, where cancer cells develop resistance to BRAF inhibitors over time, remains a significant hurdle, leading to the need for combination therapies and next-generation inhibitors. Another dynamic shaping the BRAF inhibitor market is the competitive landscape, which has intensified with the entry of new drugs and combination therapies.
Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. [ 1 ] [ 2 ] [ 3 ] Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab , Larotrectinib , Selpercatinib , Entrectinib , and Pralsetinib .
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [ 6 ] [ 7 ] It is a MEK inhibitor drug with anti-cancer activity. [ 8 ]
Approximately 98% of lung cancers are carcinoma, a term describing malignancies derived from transformed cells exhibiting characteristics of epithelium. About 2% of all lung cancers are non-carcinoma (mainly sarcoma, tumors of hematopoietic origin, or germ cell tumors. [5] These forms of lung cancer are usually treated differently from carcinomas.
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. [4] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.
Patritumab deruxtecan (U3-1402/ MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer. [ 1 ] [ 2 ] [ 3 ] References
Inhibition of this pathway was shown to enhance response and delay the onset of resistance in preclinical models. As of 2020, three clinical trials are running to test the following combinations of ALK inhibitors with MEK inhibitors: brigatinib+binimetinib, [16] ceritinib+trametinib, [17] and alectinib+cobimetinib. [18]
Ads
related to: dabrafenib and trametinib lung cancer